RECRUITING

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.

Official Title

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

Quick Facts

Study Start:2023-12-02

Study Completion:2099-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06238765

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:12 Years to 15 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:CHILD

Inclusion Criteria	Exclusion Criteria
* To be eligible to participate in this registry, an individual must meet all the following criteria: 1. Has been diagnosed with moderate to severe atopic dermatitis by a dermatologist or a qualified dermatology practitioner. 2. Is 12 - 15 years of age at the time of enrollment. 3. Meets one of the following conditions at the time of enrollment: 1. Has started taking a new Enrollment Eligible Medication within 6 months prior to the Enrollment visit. A new medication is a medication that the subject has never taken before. 2. Is prescribed a new Enrollment Eligible Medication at the Enrollment visit. A new medication is a medication that the subject has never taken before.	1. Is participating or planning to participate in a blinded clinical trial for an AD drug.

Inclusion Criteria

Exclusion Criteria

* To be eligible to participate in this registry, an individual must meet all the following criteria:
1. Has been diagnosed with moderate to severe atopic dermatitis by a dermatologist or a qualified dermatology practitioner.
2. Is 12 - 15 years of age at the time of enrollment.
3. Meets one of the following conditions at the time of enrollment:
1. Has started taking a new Enrollment Eligible Medication within 6 months prior to the Enrollment visit. A new medication is a medication that the subject has never taken before.
2. Is prescribed a new Enrollment Eligible Medication at the Enrollment visit. A new medication is a medication that the subject has never taken before.

1. Is participating or planning to participate in a blinded clinical trial for an AD drug.

Contacts and Locations

Study Locations (Sites)

CorEvitas, LLC

Waltham, Massachusetts, 02451

United States

Collaborators and Investigators

Sponsor: CorEvitas

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-02

Study Completion Date2099-12-31

Study Record Updates

Study Start Date2023-12-02

Study Completion Date2099-12-31

Terms related to this study

Additional Relevant MeSH Terms

Atopic Dermatitis